Wandercraft
Paris, 75004, France
NCT Number: NCT06715631
The goal of this interventional, national, prospective, open and monocentric study is to demonstrate that a personal exoskeleton can be used by the intended users without serious use errors or problems, for the intended uses and under the expected use conditions.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, 75004, France
The Atalante X exoskeleton, Wandercraft's first-generation hands-free, self-balancing device covered by an EC certificate and cleared by the FDA, was primarily utilized in rehabilitation institutions. However, recognizing the potential benefits of self-balancing exoskeleton technology in home settings for individuals with paraplegia and tetraplegia, Wandercraft developed a personal exoskeleton designed for home and community use.
The scope of this protocol is to validate all the critical tasks performed by the intended SCI users and companions of the device, according to IEC 62366-1(2020) and the FDA Guidance "Applying human Factors and Usability Engineering to Medical Devices.
Up to 14 participants will be recruited and will include:
Both the SCI user and their companion must complete a joint certification program to ensure safe and effective use of the device. The program is provided by a Wandercraft certified trainer and consists of five sessions spread over a maximum period of two months. These sessions include both theoretical presentations on the exoskeleton and practical hands-on training. As a precautionary measure in this usability study, a safety rail will be used to secure the user but it will not be part of the final product.
Usability will be assessed by:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
SCI user inclusion criteria:
SCI user exclusion criteria:
Companion inclusion criteria:
Companion exclusion criteria:
Before the simulated-use test, the SCI user and his/her companion must attend five training sessions provided by a Wandercraft certified trainer. Training will be composed by a theoretical part including presentation and description of the personal exoskeleton and its use modes and a hands-on practice. Each session lasts between 1 to 2 hours, varying according to the user's learning pace and tolerance. The training program is representative of the intended training for the end product.
Time frame: At session 6, after an average of 7.5 hours of training.
The acceptance criterion for this test is 100% of the trained SCI users and trained companions are able to perform each of the critical task successfully during a simulated-use test.
Time frame: At session 6, after an average of 7.5 hours of training.
Collection of observed use errors, close calls, and use difficulties and identification of critical issues during a simulated-use test - no passing criteria.
Time frame: At session 6, after an average of 7.5 hours of training.
The acceptance criterion for this test is 90% of the trained SCI users and trained companions are able to perform each of the non-critical task successfully during a simulated-use test.
Time frame: At session 5, after an average of 6 hours of training.
The acceptance criteria for this test is 100% of the SCI users and companions are able to answer to the critical task questions of the IFU questionnaire correctly and 90% are able to answer to the non-critical task questions correctly.
Time frame: At session 6, after an average of 7.5 hours of training.
The acceptance criterion for this test is 90% of the trained SCI users and trained companion rate the accompanying documents and training 3 or higher using 5-level Likert scale (1 inadequate, 2 barely adequate, 3 neither adequate nor inadequate, 4 adequate, 5 satisfactory).
Time frame: At session 6, after an average of 7.5 hours of training.
Evaluation of the SCI user and companion satisfaction and comfort on the user interfaces and use modes using 5-level Likert scales. Gather feedback on recommended changes through open-ended questions - no passing criteria.
Time frame: At session 6, after an average of 7.5 hours of training.
Measurement of the time required for donning and doffing during a simulated-use test - no passing criteria.
Time frame: At session 6, after an average of 7.5 hours of training.
Evaluation of the SCI user performance (i.e., success and timing) during a Timed Up andGo (TUG) test with the exoskeleton - no passing criteria.
Time frame: Through study completion, an average of 9 hours of training and assessment.
Assessment of the SCI user skin in the areas of contact with the exoskeleton - no passing criterion.
Time frame: Through study completion, an average of 9 hours of training and assessment.
Collection of data regarding the frequency and type of exoskeleton imbalances corrected by the safety rail and by the companion - no passing criteria.
Time frame: At session 6, after an average of 7.5 hours of training.
Evaluation of the level of assistance provided by the companion during the execution of the functional test and donning and doffing - no passing criteria.
Wandercraft
Industry
Acronym: ExoUser
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04736849
Central Nervous System Diseases, Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT05432999
Central Nervous System Diseases, Muscle Hypertonia
West Orange, New Jersey, United States
View Trial DetailsNCT03495986
Behavior, Central Nervous System Diseases
Miami, Florida, United States
View Trial DetailsNCT05776862
Atrophy, Atrophy, Muscular
Miami, Florida, United States
View Trial Details